We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 379

USPTO Guidance for examiners takes expansive view of Myriad and Prometheus decisions

  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • -
  • European Union, USA
  • -
  • March 7 2014

On March 4, 2014, the U.S. Patent and Trademark Office ("USPTO") issued a memorandum to the Patent Examining Corps with guidance for determining the

EPO appeals board declares enzymatic activity apparatus excluded from patentability

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • March 17 2014

In the patent application for Method and apparatus for measuring enzymatic activity by use of laserSony Corporation T 121310, a European Patent

AG’s opinion brings additional plant protection for safeners closer

  • De Brauw Blackstone Westbroek
  • -
  • European Union
  • -
  • March 10 2014

The ECJ ruled in GSK Biologics that an adjuvant that is part of a medical product, which adjuvant influences the therapeutic effects of the active

CJEU confirms the availability of negative term Supplementary Protection Certificates ("SPCs") in Januvia case

  • Hogan Lovells
  • -
  • European Union
  • -
  • December 8 2011

The Court of Justice of the European Union (CJEU) gave its decision in the Januvia case today, 8 December 2011

EU political update 22 - 26 April 2013

  • Clifford Chance LLP
  • -
  • European Union
  • -
  • April 22 2013

On 16 April, the European Parliament adopted a Capital Requirements Regulation (CRR) and a fourth edition of the Capital Requirements Directive (CRD

SPC update

  • Mewburn Ellis LLP
  • -
  • European Union
  • -
  • February 7 2013

The CJEU continues to receive a steady stream of referrals relating to the scope of protection from Supplementary Protection Certificates (SPCs). The

Banning human embryonic stem cells patents has the CJEU impeded stem cell research?

  • Gowling Lafleur Henderson LLP
  • -
  • European Union
  • -
  • February 6 2012

The Court of Justice of the European Union (‘CJEU’) has invalided a patent concerning the use of human embryonic stem cells (hESCs), which required the prior destruction of human embryos, contrary to the European Patent Office (‘EPO’) granting practice

Breakthrough: Europe gets the European Patent Court

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 29 2012

Europe has debated establishing a single EU Patent System for more than four decades

EU Court of Justice nixes patents for stem-cell inventions involving human embryo destruction

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 20 2011

The European Union (EU) Court of Justice has determined that EU patent law does not protect neural precursor cells and the processes for their production from embryonic stem cells

An EU patent court for London

  • Shepherd & Wedderburn LLP
  • -
  • European Union, United Kingdom
  • -
  • February 22 2013

The members of the European Union have been trying to agree on a unified patent for around forty years. The EU has managed to agree on a Community